When I came into radiotherapy in 1950, I was puzzled that some patients were treated to 3000 rads (cGy) in 3 weeks but others received 4000 in 5 or 6000 in 6 weeks. When I asked why, there were no convincing answers given, except 'this is what we usually do'. It wasn't until I went to a course on 'Radiobiology for Radiotherapy' in Cambridge that I learnt about the basic theories of Douglas Lea and the very considerable history of research into radiobiology and clinical radiotherapy. And there were still some questions outstanding, such as the relative importance of intracellular repair between 'daily' fractions, whether a 2 day gap each week was a good or a bad idea, and the role of proliferation, if any, during irradiation. I thought that a few simple animal experiments might help to give answers! That led me to a continuing interest in these questions and answers, which has taken me more than 50 years to pursue. This is the very personal story of what I saw happening in the subject, decade by decade. I was happy to experience all this together with scientists in many other countries, and our own, along the way.
Introduction
We didn't call it the 'Golden Age of Radiobiology' when we were working at it, but that's what some reviewers are calling it now. When I came into the field as a hospital physicist in September 1950, I was told "don't go into 'radiotherapy'-that subject will soon be considered a crude old method-cancer will be cured by 'a spot of the jabs'." (They were talking about immunotherapy then.) But just look at radiation oncology now (Bentzen 2005a ). The present account concerns the question of 'iso-effect doses', at the heart of non-standard fractionation and what is now called 'biological optimization'. This review provides my personal reflections and experiences on the development of radiobiology, particularly radiobiological modelling, 1 Present address: Kirk Cottage, 1 Church St, Bovingdon, Herts HP3 OLU, UK. Alpha and beta are the coefficients of the non-repairable and the repairable components of radiation damage respectively. Alpha is the number of logs(e) of cell kill per gray; beta is the number of logs per gray-squared. The beta-component represents mis-repair as well as repair: a cell with a high beta would be good at both. This describes the rapidly falling survival curve seen at a high β/α, i.e. a low α/β ratio, characteristic of slowly proliferating cells. The beta component fades with a half-time of minutes or hours, so that a very low dose-rate is close to the alpha curve.
over the last 50 years. I'm sorry if it appears boring, because it is mostly old stuff. I've therefore added some scraps of peoples' data. I hope my occasional 'forward-flash' will not be too confusing; each section is still based on a given decade only. After another 55 years, radiotherapy has developed much better means of irradiating tumours and avoiding normal tissues, while simultaneously recording the dose received by every small volume element, to correct almost immediately any underdosed or overdosed voxel (Mackie 1999 (Mackie , 2003 . . . with a growing library of new methods of imaging so as to enable the powerful computerized physics to aim at the right targets, embedded in tissues now known to be constantly in motion from breathing and pulse artefacts, as well as with set-up uncertainties . . . in departments with five or six times more specialist radiation oncology staff, both medical and non-medical, than in the 1950s. How did we manage to cure any cancers at all then? Indeed I was still being told, in the 1970s, by a physician from another subject on a Medical Research Council (MRC) Cell Board that 'no cancer was cured by radiotherapy except skin cancer'! Thus the teaching, or lack of it, at Medical School can stick for later generations to prejudice appreciation of real improvements. I wish to describe the role of radiobiology in helping to sort out the questions of iso-effect in non-standard fractionated radiotherapy, and ultimately of optimum radiotherapy. Since about half this story concerns the linear-quadratic (LQ) formula representing the shape of cell survival curves, I'll introduce that without delay as figure 1. But wait for it to emerge slowly from the story! In writing this I've been impressed again with how much I owe to dozens of people who went before all of us, and dozens more who helped me personally. I've enjoyed playing a small part in some of the developments in radiobiology that I've been lucky to be still alive (at my age) to see.
Most developed countries have well-organized regional radiotherapy centres, each of which services several million patients. Half of all cancer patients receive radiotherapy at some stage of their disease, an increasing proportion of whom achieve long-term cure; with an increasing proportion of early diagnosed patients in whom the chances of cure are now exceeding 90%, for example in T1-T2 tumours in breast, oropharynx, prostate and even lung (Kaanders 2002 , Demanes et al 2005 , Song et al 2006 , Nagata et al 2004 , Nihet et al 2004 . It is also being realized that the cost of radiotherapy is less than that of surgery and very much less than that of chemotherapy (Lieven and , Lieven et al 2005 .
Early experiences of a young radiation physicist turning into a radiobiologist
When I was a young hospital physicist at Newcastle-on-Tyne in 1950, I was puzzled by the radiotherapists (as radiation oncologists were called then) who prescribed 4000 rads (as cGy were called then) for some patients and 6000 for others. We physicists knew that we could measure doses to better than 1%, and deliver them within 5% most of the time, so we didn't understand this uncertainty. When I asked 'why such different doses?', I was told 'that's the cube root law' or 'because Ralston Paterson's book says so', and their knowledge obviously didn't go much further. I became interested in the theoretical aspects of cell kill and dose rate raised in Hal Gray's series of eight papers (on bean-roots and more) which were just appearing at the time in the British Journal of Radiology (BJR) (Gray and Scholes 1951) . The physicists respected them, but most radiotherapists (radiation oncologists) thought that bean roots or tadpoles were irrelevant to patients with cancer to be treated that month, that year-no waiting for 25 years thank you! Clinical observations were however accurately made, and I was once caught out as a physicist by a radiation oncologist who said 'you haven't calibrated that x-ray set for 3 months have you, because the skin reactions have changed over that time'. And he was right. But he thought the same once or twice later, and he was never right again! It kept us physicists on our toes, and gave us great respect for clinical observations by conscientious observers.
It wasn't until I went on a two-week course on 'The Radiobiological Basis of Radiotherapy' given by Professor Joseph Mitchell at Cambridge about 1952 that I learnt about the many clinical and animal studies that had contributed already to the practice of radiotherapy. And about the oxygen effect and some of the theories of radiation action of Lea and Catcheside (1942) and Lea (1947) . And about the long clinical arguments between the German school of radiotherapy that favoured a few big fractions (or even one), and the Austrian and French schools of Freund and Schwarz, later Regaud, Coutard and Baclesse that had, apparently a few years before World War 2, established that many small fractions were better (Thames and Hendry 1987) . At about the same time, Eric Hall at Oxford published a convincing explanation of how cell sterilization could explain the changes in bean root length caused by irradiation. I became fascinated by the unknowns still present in the use of different schedules of fractionation. How much of the increase in total dose with increasing overall time was due to repopulation in the irradiated tissues, and how much instead to intracellular repair between successive small fractions?
My first hands-on irradiation was a rabbit to be given a whole-body dose at King's College Hospital in Denmark Hill, for a haematologist, Dr Davidson, in 1956 . No rabbit was ever planned so carefully, on a slowly revolving platform in front of a stationary 250 KV beam, with Perspex body-phantoms to do preliminary dosimetry, and the animal survived, as was intended. I admired in 1957 Dr Charles Wilson's three-point arbitrary scale of biological response that he was using to score effects of radiation on bone healing: 0 no observable effect, 1 slight, 2 marked, 3 strong. I felt that it was a move into quantification that biology appeared to need and that physicists could certainly do, even an amateur like me.
Radiobiology in the 1960s
At that time the major interest for radiobiologists interested in radiotherapy was the nature of 'iso-effectiveness'. How could one fractionation schedule be compared with a different schedule, in particular to choose the same normal-tissue complications if a different schedule, or even a different type of radiation, was to be used? Curiosity ranged from fundamental models of shapes of cell survival curves to clinical multi-fraction data. There were almost no data on multifraction animal experiments; just the rams and rabbits of Regaud and Ferroux (1927) and the pig skin experiments of Wachsmann (1943) .
Together with Babette Stern from the Royal Free Hospital, whom I met on the Cambridge course, we tried to extract rates of cellular recovery after irradiation from a number of published clinical dose-response versus overall time relationships. Our conclusion was that there were two rates of recovery, one occurring in a few hours that we would now call molecular (intracellular) 'repair', and the other occurring over days and weeks, thought to be 'repopulation'. We expressed this arithmetic in terms of the simplest mathematical nonlinearity, which is linear quadratic (with a sigh of relief that it didn't seem to need a dose-cubed term as well)-a derivation from Lea and Catcheside (1942) . We wrote a paper that was turned down, very politely, by the British Journal of Radiology-the Editor, Professor Lamerton, came by my office and told me personally, and I was very impressed at this unusual courtesy-on the grounds of 'speculation with no convincing evidence'. It was published several years later (Fowler and Stern 1963) , but only after I had been invited by Tikvah Alper to talk in a symposium at the BIR on 'Radiobiology Applied to Radiotherapy', so I had become 'respectable'. Its main contribution was to show a summarized curved line relating log response of skin to log overall time, in place of the straight line claimed by Strandqvist (1944) to have a slope of 0.22 and by Cohen (1952) to have a slope of 0.33. About which more later.
At meetings at the BIR in Welbeck Street, about 1960, I heard Hal Gray describe the cell survival curves of mammalian cells first grown and irradiated by Mortimer Elkind (Elkind and Sutton 1960) . The sense of occasion was much heightened by Harold Hewitt's announcement that he had extracted viable cells from mouse cancers, and that just two cells were enough to grow another tumour in another mouse, the cell survival curve having a similar slope (1/D o ) to those of Mort Elkind. Radiobiology then became heavily concerned with cell survival curves and many ingenious interpretations of radiobiological phenomena were made with sketches of such curves, often on lunch and dinner napkins. People speculated that if the 'hit numbers' were about 2 (where the alleged straight line of slope 1/D o extrapolated back to zero dose), this might represent the two strands of DNA as targets for radiation damage . . .. Yes, it was all very exciting, but that idea didn't survive the enormous range of extrapolation numbers found in different cell lines (meaning a large range of repair capabilities), nor the discovery that cell survival curves in vitro were often curved instead of straight (Barendsen et al 1960) . Barendsen et al's paper was published in the same volume of Radiation Research as the much more quoted paper by Elkind and Sutton, but the Dutch were right up there too as pioneers. It was soon found that hit numbers for different cell lines in vitro were spread from 1.0 to many hundreds, so Tikah Alper changed their name from 'hit number' to 'extrapolation number', which still stands. Withers (1967) , working with Hal Gray at Mount Vernon in the early 1960s, developed a way of counting individual surviving cells in situ, in mouse skin irradiated in a 1 cm circle of skin surrounded by a truly overdosed annulus of skin to limit the target area. Cell survival curves for mouse skin could thus be generated by counting these 'clones', and the influence of hypoxia and of split-dose repair was demonstrated directly in situ. He went on to work with Mort Elkind in Washington and there developed a similar method of counting individual surviving cells (clones) in the small intestine of mice, which has been much used. Fowler et al (1965) developed a skin-reaction system for mouse foot based on scores of 0, 1, 2, 3, and could then derive surrogate cell survival curves indirectly, in situ in mouse skin. Individual mouse skin reactions could be observed sequentially for days or weeks without having to sacrifice the animals for pathology. The derived cell survival curves were arguably, but not convincingly enough, curved, so the old 'target dose' survival curves with a 'hit number' and a straight semilog slope of 1/D o still held sway for another 20 years and longer. In Madison for example, where I went to work 25 years later, I had to argue strongly to get people to take any notice of linear quadratic instead of 'n and D o '. Back in the 1960s there was much dispute about whether cell kill (strictly sterilization) and hence cell number depletion, was or was not responsible for the major observations of tumour control (plausible) or of normal-tissue damage to skin and other organs (highly arguable at the time), especially for late complications. Alper and Hornsey (1973) produced the most convincing evidence at these early times (figure 2.1 in chapter 2 of the Thames and Hendry book (1987) ). They showed that several x-ray or neutron schedules of equal lethal effect in the whole animals also provided equal cell kill of cell colonies in the small intestine of rats. This wasn't well accepted until some ten years later (Alper 1973 , quoted by Thames and Hendry (1987) ) loc. cit.
A major impediment to radiobiology in the early 1960s was that multiple fraction experiments, beyond 2-fraction or 'split-dose' irradiations, could rarely be done in experimental laboratories, with the notable exceptions of Professor F Wachsmann in Germany with pig skin and the Du Sault sisters in Detroit with mouse tumours, whose work we followed with interest. Elsewhere, single-dose experiments were most common, so that the effects of multiple small fractions were not well known at all. Elkind's 'repeating curved cell-survival shoulders ' (1960) however provided a good lead to what might be happening: repair between successive fractions, confirmed by our own experiments (Fowler et al 1965) and Withers' (1967) experiments on mouse skin in London. There was much argument about whether the 'initial slope' at very low single doses was finite or actually zero, as suggested unfortunately by the theoretical 'n and D o ' formula. This was really settled experimentally much later by the work at Vancouver using their computerized colony counting to trace individual colonies (Palcic and Skarsgard 1984) , and theoretically by the linear-quadratic theory. Zero slope it was not! Barendsen et al in Rijswijk and Jean Dutreix et al in Paris were much involved in such discussions and experiments.
The opportunity to do relevant fractionation experiments on cells and animals
When I moved to Hammersmith in 1959 I felt I was moving to the one of the 'centres of the world of radiobiology'. Important basic discoveries had been made at Hammersmith: Howard and Pelc (1953) first described the phases M, G1, S and G2 of the cell cycle; Thomlinson and Gray (1955) explained hypoxia in human tumours in terms of competing diffusion out of blood vessels and consumption of oxygen by cells; Wright and Howard-Flanders (1957) delineated accurately the change of mammalian cell radiosensitivity with oxygen tension in cells. When Gray was dismissed from Hammersmith in 1954, because of a disagreement about his extensive plan for research instead of starting to treat patients 'too soon' with neutrons, it sent a tsunami of discontent across the radiation research community. This happened because of MRC Head Office misunderstandings and their hierarchical approach. Fortunately Gray was soon re-established by the British Empire Cancer Campaign in a new laboratory built for him at his former hospital, Mount Vernon at Northwood, now the Oliver Scott Building of the Gray Institute. But it took five years before experiments on clinical applications could be planned in the MRC Radiotherapeutic Research Unit at Hammersmith. I replaced Dick Newbery, the head physicist there, in 1959 when he retired. With David Bewley and others we were able to compare 5 fractions of x-rays in a week with 5 fractions in 4 weeks in a series of experiments on pig skin. These demonstrated more effect of fraction size than of overall time, but some of both (Later this was not in conflict with Frank Ellis's NSD concept (1969) which assumed that Strandquist's slope of 0.22 related to fraction size and number, while the difference between that and Lionel Cohen's slope of 0.33-that is, 0.11-was attributed to overall time.) In the laboratory 'fractionated' had usually meant two fractions, and we had managed to push it up to five.
At Hammersmith Hospital MRC Unit we made it to 20 fractions (F) of neutrons in 4 weeks on pig skin, in experiments designed to obtain relative biological effect values (RBEs) for neutrons versus x-rays. Quite heroic efforts from many staff, mostly young physicists and cyclotron engineers, who sometimes had to carry pigs from the roof on the tenth floor to the 15 MV cyclotron or the 8 MV linear accelerator on the ground floor, if the lift failedfortunately it did so only occasionally.
Herman Suit at the MD Anderson Hospital in Texas was one of the first radiobiological investigators to have a dedicated laboratory facility to do multiple-small-fraction animal experiments designed to simulate radiotherapy fractionation realistically. Even Hugh Thomlinson at Hammersmith in the early and mid 1960s, who did splendid experiments demonstrating the effect of hypoxia in rat tumours and its time course of reoxygenation (hours), was limited to a spaced pair of large doses, 10 or 20 or 30 Gy. Meanwhile, at Hammersmith, my physics team of amateur biologists, advised by Hugh Thomlinson, Tikvah Alper, and Shirley Hornsey, embarked on an ambitious scheme of irradiating a number of 4 × 6 cm skin fields on the sides of young adult pigs (80-100 lb) to determine neutron RBEs (radiobiological effectiveness = x-ray dose divided by the neutron dose to cause the same effect), with control animals treated by standard fractionation of 200 rads × 30F in 6 weeks, in the afternoons after patients' treatments had finished (so as to avoid the pig smell bothering any patients in the 8 MV linear accelerator). (A rad was the same dose as a present cGy.) The neutron pigs were treated in the cyclotron chamber under remotely controlled anaesthesia, a considerable development of technique on its own. Out of this work came the realization that RBE was highly dependent on dose-per-fraction, in a way that could be quantitatively predicted by the highly curving x-ray cell survival curves in contrast to the almost straight neutron cell survival curves. I once had an informal meeting with Hal Gray at the BIR and explained our current results on the neutron RBEs, about 1964. He laughed and laughed, in that hugely infectious laugh of his, but didn't tell me why. Later I gathered that that was exactly what he had predicted more than ten years earlier, from his Broad Bean experiments, before mammalian cell clones were available. Ten years later I discovered that because of his loud laugh, Hal Gray's office at the British Empire Cancer Research Campaign Radiobiology Research Unit at Northwood had been built with double brick walls, to avoid interrupting his colleagues' thoughts and discussions.
Much later it became clear that a neutron cell-survival curve should not be drawn with a tiny curved shoulder at the lowest dose followed by a straight 1/D o dose-response curve, but should instead have a long straight initial portion, gradually bending over into a barely perceptible, but progressively increasingly steeper, curvature at higher doses. This realization (from reconstructed multifraction skin experiments) was one of the most convincing demonstrations of the LQ model when it became relevant to in situ experiments, ten years later. Especially convincing for Julie Denekamp, who always claimed she didn't like the minimal algebra used in LQ modelling, even though she could in fact handle it very well.
We had planned to follow-up the irradiated pigs for one or two years. We felt that the control pigs (x-ray schedules only) were likely to give us as much valuable information about fractionated radiotherapy as the neutron experiments. When the pigs grew to full weight, of one or two hundredweight, they were taken to a farm some miles away, instead of staying on the Cyclotron Building roof at Hammersmith Hospital. However, the Medical Research Council, in a spectacular piece of mistiming, decided to close down its Radiotherapeutic Research Unit at Hammersmith in 1961, when the Director, Dr Constance Wood, retired in 1962. They were entirely entitled to do this legally, and closing Units always looked good in the top-level reports. Staff left and our pig follow-up was not done. Much later, the subject of radiation oncology has recovered (and the MRC Cyclotron has become the new General Electric Company (GEC) Positron-Producing Centre). However, our late effects on pigs were only clarified 20 years later, by Withers et al (1982a) , on pigs in Texas, when the linear-quadratic formulation was available to explain very logically the different effect of size of dose-per-fraction on late and early skin reactions.
I then spent an illuminating year with Professor Joseph Rotblat at St Bartholomews Medical School, learning about the dedication of university teachers, especially at examination time! With Patricia Lindop we developed the mouse foot skin scoring system of three objectively characterized levels (Fowler et al 1965) , which has since become used in other centres too (Moulder and Fischer 1976, van Rongen and Kal 1984) .
In 1963 I returned to Hammersmith to establish a new University Department of Medical Physics and soon acquired a small team of postgraduate students, some on radioisotope scanning with John Mallard and later Harold Glass, the others on radiobiology with me. The first was Julie Denekamp, fresh from a first Class BSc in Biology. (She couldn't follow her first preference which was Marine Biology, because of sea-sickness, although she was the daughter of a Dutch sea-captain.) Others during seven years included Tony Howes, Jolyon Hendry, Mossaad Hegazy, Adrian Begg, Fiona Stewart and Sally Hill, all of them now distinguished in associated topics. The last three moved with me to Mount Vernon when I was invited there in 1969. I was very flattered to be asked to be asked to follow Oliver Scott when he retired as Director of the British Empire Cancer Campaign (BECC) Research Unit in Radiobiology (RUR). Glory indeed, to follow Hal Gray there too . . . and fewer University committee meetings than Professors had! The BECC became the Cancer Research Campaign (CRC) and the RUR became the Gray Lab (now the Gray Institute Trust). Nick McNally joined the Gray Lab from Hammersmith a few years later.
Opportunities to do some definitive experiments
During our seven years at the Royal Postgraduate Medical School at Hammersmith Hospital, this little team in one quarter of the Medical Physics Department carried out many experiments on the radiation reactions in mouse skin and rat tumours, in happy collaboration with the MRC Cyclotron Unit. They were building up the picture of 10% of labelled cells proliferating in the basal layer, then progressing at their usual rate through the differented layer towards the superficial squamous epithelium, there to flake off naturally in about 5 days in mice (Hegazy and Fowler 1973) . Irradiation would cause proliferation in the basal layer to decrease, so that flaking off would occur after a few days delay, longer in fractionated irradiation and lower doses. After higher doses a moist desquamation reaction could occur. This would later heal up, or not, depending how many cells per mm 2 survived the total radiation depletion minus repopulation. Julie Denekamp modified our 3-point scale to include 1 4 points, giving a 12-point scale (Denekamp 1973 ) and we learnt to avoid the moist desquamation reactions in nearly all of our mouse experiments. Some of the skin cell kinetic work was done in collaboration with Norwegian cell kineticists (Iverson et al 1976) , using thymidine autoradiography.
An important step in radiotherapeutic understanding was made by Denekamp (1973) while at Hammersmith, published in the BJR 3 years later, using the technique she developed of 'top-up doses'. First a single-dose response curve would be established for the strain of mice to be used, at the kilovoltage of x-rays to be used. This would be designated 'singledose-only'. The full treatment to be investigated was 20 fractions of 300 rads of x-rays (300 cGy) given in 4 weeks, so a dose-response curve was next obtained for that full schedule, reading the skin reactions every day for 3 weeks after the last irradiation, and averaging them to obtain an ED-50 for the full schedule. (ED50 is the dose at which 50% of the mice reach a stated level of skin reaction) The experiment was to determine the ED50 at various intervals before the end of a full fractionated schedule. After say 15 fractions in 3 weeks, a test single dose would be delivered immediately after the last of the 15 fractions, followed by the usual daily readings of skin reactions on the mouse legs to establish another dose-response curve. This dose-response curve would have its centre point (ED-50) at a dose to the left of the single-dose-only curve, and the difference from the single-dose-only curve would indicate the dose equivalent of the 15F schedule. The top-up method has since been validated many times, later using neutrons as top-up doses to minimize intracycle variations of cell radiosensitivity (Joineret al 1986).
Thus the dose equivalent of the 15 fractions including any repopulation occurring during its 3 weeks of irradiation was determined. This procedure was repeated for 5 and 10 fractions in 1 and 2 weeks respectively, to build up a profile of the time course of repopulation during 'daily' fractionated irradiation of mouse skin. It was thus discovered that repopulation did not follow a power law as previously thought, but instead had a delayed start, then a rapid increase of repopulation continuing for as long as the depletion by daily irradiation continued. As figure 2 shows, this time course was strongly contrasting with the assumption made by the 0.11 power law of the 'Cohen minus Strandqvist slopes = Ellis's NSD' (Nominal Standard Dose) concept. It wasn't the only criticism of Ellis's NSD that was emerging, but it strengthened the criticisms. All of this picture of repopulation in skin was confirmed by detailed radioautographic sections, with labelled cells and labelled mitoses, counted in the laborious cell-counting microscopy that was a major adjunct to the skin-reaction scoring of the in situ experiments.
At the same time that we were obtaining RBE's from the contrasting shapes of the derived dose-response curves in pig and mouse skin, we were also collaborating with Dr Eddie Barendsen from Rijswiik in The Netherlands on the MRC cyclotron, who was visiting us and measuring similar shapes in in vitro cell survival curves as a fundamental investigation into size of targets in nuclei of mammalian cells (Barendsen et al 1963) . These different experiments meshed together extraordinarily well.
Animal radiobiology in the 1970s
In 1970 computer work was done by sending paper tapes to the University Computer Centre elsewhere in London and waiting for the output tape to be sent back for printing out. We were skilful at slide rules and reading accurately off mm graphs, and we tested each other in graph-drawing competitions which Julie Denekamp often won (although she said she didn't like maths). Our earliest experiments were on mouse skin reactions as described above, so investigating the time courses of these reactions, and also of several types of mouse tumour, had made us very aware of the rapid rate of repopulation in many of those tissues, even during continuing daily irradiations: 'Radiotherapy may be thought of as a two-horse race, between tumour repopulation on one hand and the acute skin or mucosal reactions on the other hand . . . '.
In 1970, five years after Hal Gray had died, my little team and I moved to Mount Vernon Hospital, to the BECC Radiobiology Research Unit. I was appointed Director, with Barry Michael, Harold Hewitt, Ged Adams and David Dewey already there and Julie Denekamp and Nick McNally also to become Heads of the Sections. It was soon renamed the Gray Lab and was enlarged to contain a new animal house with three 250 kV x-ray machines inside the sterile animal quarters. This design, and a high productivity of clean and inbred mice from Angela Walder, enabled us to do multi-fraction animal experiments on mice, as we had always wanted to do them. Just as many experiments were carried out on normal-tissue radiation effects as on tumour cure or regrowth delay. At that time the hypoxic cell radiosensitizers were just being discovered and characterized (as electron-affinic) and not too toxic (not too lipophilic), and much work went into the testing of them both in vitro and in normal tissues and various types of tumours in mice. By about 1994 it appeared that the good radiosensitizer Roche 0582 (later called Misonidazole) worked best when the radiotherapy schedule was substandard, for example either too short or too long in weeks. For optimal radiotherapy however it gave only a small gain in tumour effect (the sensitizer enhancement ratio, SER). This was thought to be due to the successful reoxygenation of at least most of the hypoxic tumour cells by a good radiotherapy schedule . This was published as our first paper in the International Journal of Radiation Oncology, Biology and Physics (the Red Journal), after a delay of some 2 years. However, nobody seemed to want to know that interpretation. There were arguments about the relevance of mouse pharmacological doses of radiosensitizer to doses in human subjects, but eventually the plasma concentrations were found to be relevant for the SER, rather than some folklore-ish rules.
The optimists still wanted to go ahead and test it in human tumours, and this was indeed done thoroughly in many well-organized clinical trials. The results several years later were as disappointing as the best of our mouse tumour fractionation results had been. At the same time the Gray Lab concentrated on developing new methods of exploring late radiation reactions by studying mice during their lifespan after irradiation, instead of sacrificing samples for pathology at intervals. The mice were always given partial-body irradiation to shield all parts except the target organ or tumour, sometimes using electron irradiation. (Travis et al 1979) . (3) Anaemia changes in plasma, not whole blood, at 6 months that measure kidney damage with good sensitivity (Alpen and Stewart 1984) . (4) Urination frequency to measure bladder damage (on a moving filter paper underneath mouse cages), at selected times after irradiation, with dye and UV irradiation to identify the urine spots more readily (Stewart et al 1978 (Stewart et al , 1980 (Parkins et al 1983, including Professor Shen Yu from China) .
Fiona Stewart and Julie Denekamp discovered, in labelled cell autoradiography in the Gray Lab, that gross late complications occurred at about the same time as the labelling index rose again after irradiation in its natural cycle, which had the duration of a year in mouse bladder (Stewart et al 1978 (Stewart et al , 1980 . This identified the natural pre-irradiation turnover time (T pot , potential doubling time, Steel 1967) of a normal tissue as the main controlling factor of whether the important radiation damage in an organ occurred early or late. For some types of late injury, the slow proliferation in normal blood vessel walls was the precipitating factor. Denekamp et al (1983) showed that the only rapidly proliferating cells in blood vessel walls were in tumours, or in foetuses, or in wound healing. This gave impetus to the development of anti-angiogenic drugs for cancer treatment, which are still being developed.
We were greatly helped by a series of enthusiastic and bright young MDs or PhDs who continued the tradition of spending a year or two at the Gray Lab, including Eli Glatstein, Rick Brown, Lester Peters, Dennis Shrieve, John Moulder, Elizabeth Travis, Janet Rasey, Marvin Goldman, Anna Gasinska and others. Apologies for many omissions! In the mid1970s, a young engineer-turned-radiation-oncologist called Bruce Douglas came to work on fractionation in radiotherapy at the Gray Lab, with a post-doctoral scholarship from Vancouver. His grandfather had named the Douglas Fir, and Bruce was an enthusiast about roses. After brief discouragement away from using LD50 experiments, he agreed to use the acute skinreaction system and quickly designed a system of three small pillars which held one hind leg of a mouse. The mouse was enclosed in a lead box, with only its leg exposed to the x-ray beam in a circle of five lead boxes, to irradiate the legs of five mice simultaneously. With this set-up much work was done. The upshot was a series of fractionation experiments using one to 64 fractions, of size from 23 Gy to 1 Gy per fraction.
The 'traditional' plot of total isoeffective dose against fraction number showed a clearly curving line (figure 3), instead of the straight log-log lines mandated by a power law. What Bruce did was to plot it instead as reciprocal total dose, because simple algebra demonstrated that this would only be a straight line if the cell survival curve of the critical (basal) cells had a linear-quadratic form. The data then demonstrated a straight line relating reciprocal total dose to dose per fraction, and linear quadratic reared its head for multiple equal fractions (figure 4).
Further, reconstruction of the resulting iso-effect doses, divided by the fraction number for each fraction size, showed a very large shoulder, continuously bending to form the cell survival curve (figure 5, Douglas and Fowler 1976) .
This demonstration that the linear-quadratic formula applied to gross reactions in tissue in situ came from these mouse experiments. However its application to clinical radiotherapy did not materialize until four or five years later. These experiments were the ones in which a bulldozer in the hospital grounds dug up both the main electricity cable and the hospital water supply. We had only 6 h intervals in that phase of experiments. The day was saved by two items. The local electricity company willingly provided a motor generator on a large truck, and the Gray Lab had earlier been fitted with a 4000 gallon water tank on the roof, although the Cancer Research Campaign's sharp accountants had needed much convincing by me a few years previously that we really wanted such a large water tank for just such experimental continuity. Douglas and Fowler (1976) , replotted from their table 2. The contrast from the straight log-log lines of the previously utilized power laws is clear. (1) and (2), that log cell kill E = n (α + βd 2 ) = nd (α + βd); so that E/nd = (α + βd) where n is the number of equal fractions of d Gy, which is total dose. The intercept on the Y axis is E/α and the slope is E/β, so their ratio gives α/β.
Meanwhile, Rod Withers, back in the USA, had an enforced gap in animal experiments due to delays in building a new animal laboratory for him when he moved from Houston to Los Angeles. He put this to good use by thinking more about the multi-fractionation experiments that he and Herman Suit, and we, and Barendsen and Van der Kogel and others had done. Instead of plotting 'total tolerance doses' against fraction number, he plotted them against dose-per-fraction. He then saw that the slowly proliferating, late-reacting, normal tissues all had much steeper slopes (more sensitive to fraction size) than the rapidly proliferating, early reacting, tissues. Most tumours were in the rapidly proliferating group. This major observation fitted in not only with our own animal experiments on skin versus kidney tolerance for example, but also with clinical observations from San Francisco (on lung and brain) and from Sweden (skin reactions in breast treatments), and the whole major late-versus-acute picture emerged (Withers et al 1982b) . The difference between the late and early normal-tissue reactions had not emerged from Frank Ellis's NSD or TDF concept, nor immediately from Barendsen's extrapolated total dose, ETD. But all the attempts to fit animal and clinical data to any of those earlier concepts did help to lead to the differences now becoming clear. In spite of valid criticisms, Ellis's NSD was still widely used, and a somewhat different variant (different in time factor) was proposed by Kirk et al (1971) of Glasgow, the Cumulative radiation Effect, CRE. Meanwhile Ellis's NSD had been converted to 'only-too-convenient' tables by Orton and Ellis (1973) . When I went to work in Madison in 1988, every radiation oncology resident had a copy of them in his or her pocket! However, the US Residents took quite rapidly to LQ when I visited various medical schools to explain it (in terms of the Seven Steps to Heaven, see below).
Radiobiology in the 1980s
In my opinion the pivotal point of the iso-effect or 'equivalent fractionation dose' conundrum was established when Eddie Barendsen at Rijswijk did a few more lines of inspired algebra with the LQ formula and proposed the 'log cell kill' as the basic standard of comparison between different fractionation schedules, avoiding entirely any idea of an 'equivalent single dose' which had haunted all previous attempts to rationalize the subject. He called his construct the 'extrapolated tolerance dose', ETD, meaning extrapolated to zero dose-per-fraction or very low dose rate. He used a term called relative effectiveness (
which is still one of the most useful terms in the LQ formulations. He proposed that it should be applied to normal-tissue complications, for any stated dose-per-fraction and total dose that represented the tolerance dose for a given organ. However, although he did not pick up the difference just described between late and early reactions, Barendsen's construct and the emphasis on the ratio α/β (which he preferred to call a 1 /a 2 ) soon led to the rationalization of the whole subject in terms of linear quadratic as we know it today. The α/β terminology was preferred by Howard Thames who preferred it to the more mathematically traditional a 1 /a 2 , thus making printing-output difficulties that persist to this day. Does your printer ever come up with a pair of open squares instead? Several years of intensive experiments to establish the α/β values for many normal tissues and types of mouse tumour followed at the Gray Lab. Barendsen's paper was drafted in 1980-I have a copy-but the Red Journal took two years to review and publish it (Barendsen 1982 What hasn't changed, to our chagrin, is the amorphous situation of the solution to the hypoxic cell problem. Although hypoxic cells are disastrous if they remain present in a tumour during treatment, does ordinary fractionated radiotherapy eliminate them by reoxygenation in most tumours? Evidence has been presented that among 8000 patients, only 5% suffered from this disadvantage (7% in head-and-neck, Overgaard 1994) . With any luck, and some seriously strong will, it ought to be possible to predict, before an individual radiotherapy treatment has gone many days, whether extra measures need to be taken in that patient to deal with hypoxic tumour cells that are failing to reoxygenate sufficiently (Nordsmark et al 2005 , Bentzen 2005b ).
The Seven Steps to LQ Heaven, defined as 'easily understanding the LQ formula for BED, and remembering it next week'
When it was realized that Barendsen's ETD concept could be applied to any level of dose or biological damage, including tumour cell kill, not just 'Tolerance of normal tissues', it was renamed ERD (extrapolated response dose), by which it is still known in some countries, especially The Netherlands. It took another seven or eight years, and the acquirement of flow cytometry results on the rapid proliferation of T pot (potential doubling time, i.e. the birth rate of cells in the relevant tissue (Steel 1967.) to add a term representing repopulation of cells during continuing 'daily' irradiation to then produce the biologically effective dose of the 'Seven Steps to Heaven'. by which the LQ formulation is most conveniently taught (Fowler 1989 (Fowler , 2006 . The term BED turned out to be popular, but is occasionally used wrongly, that is not according to equation (4) or (7). E = log cell kill from n fractions of d grays
(1)
To obtain a 'BED' we must divide by either α or β; and α gives us a more convenient number, actually in units of dose, than dividing by β, which would give a number in dose-squared (which Thames suggested as Total Effect); Barendsen chose E/α:
Equation (4) gives us 'BED' (or ERD) = log cell kill by radiation ignoring repopulation (Barendsen 1982) . Fowler (1989) suggested adding a subscript to BED comprising the α/β ratio assumed, to clarify that this is a derived 'biological' dose, not a real physical dose; and to identify the tissue α/β value assumed. Not adding such subscripts results in confusion between 'biologically equivalent' and real physical doses. Unfortunately you can see this error occurring in some published papers.
Then we need to subtract the log cell repopulation from the log cell kill. To do this we have to assume several more parameters. First we assume an α/β ratio for the tissue irradiated (e.g. α/β = 10 Gy for rapidly proliferating and most tumour tissues, but α/β = 2 or 3 Gy for late complications. Then we can assume a nominal alpha-value (e.g. 0.3 or 0.35 log e /Gy). Next we assume repopulation starts at the kick-off or onset time T k days and continues until the end of the schedule at T days; so that the time available for proliferation is T − T k days. Finally we assume a constant doubling time of T p , after T k . Note that T p is not T pot , which is the doubling rate before any disturbance by radiation or other agent. It is the average doubling time between T and T k , as a result of cell depletion which stimulates repopulation. Unfortunately Eric Hall omitted T k in his otherwise very fine book (Hall 1994, 4th & later editions) but its omission leads to much confusion, especially if a range of overall times is being considered which happens to include T k in the middle!
BED = log cell kill by radiation minus log cell generation by repopulation in the time (T − T k ) days. (Fowler 1989 ).
Since the most influential variable in this formula is the ratio α/β, equally with doseper-fraction, it is usual to designate a BED by means of a subscript, such as 100 Gy 3 for late complications (assuming α/β = 3 Gy) or 75 Gy 10 for acute BED or tumour BED (assuming α/β =10 Gy). This not only clarifies at once what tissue we are talking about, but it also distinguishes between a physical dose and its 'biologically equivalent' conceptual dose. The ratio α/β then becomes a parameter that is a surrogate for 'type of tissue'. Failure to use these subscripts leads to much unnecessary confusion. Note than BED means biologically effective dose, and the 'equivalence' is a simply derived concept from the LQ arithmetic, best expressed as the NTD ('normalized total dose in 2 Gy fractions'), or occasionally as LQED (figure 6).
This algorithm has remained remarkably robust for more than 20 years. It has given helpful predictions of the relative strength of many clinical fractionation schedules, from non-standard schedules for head and neck radiotherapy or lung Ca to low-and high-dose rate brachytherapy for carcinoma of cervix uteri or prostate (Mehta et al 2001 , Fowler et al 2003a , 2003b , Fowler 2005 . The trick is to keep the predictive modelling simpleassume only a few well-accepted values for the parameters, including those mentioned in 
, where d is dose-per-fraction and α and β are the usual linear and dose-squared coefficients respectively. BED is the dose that gives the same level of cell kill if it could be given as an infinite number of infinitely small fractions, i.e. at very low dose-rate. This extreme multi-low-fraction cell survival curve would then have the same slope as the alpha component alone, which is also the initial slope of the single-dose cell survival curve, = alpha. A more general multifraction curve, representing n equal fractions of d grays each, is equation (4) in the 'Seven Steps to Heaven'. It is steeper than alpha by the amount of relative effectiveness, RE. For equivalent effects it terminates on the horizontal line E.
this section, and do not get into 'elegant variation' for α/β ratios (for example, nearly always use the generic values 3 Gy for 'late' and 10 or 30 Gy for tumours) or for values of T k (21-32 days) or T p (2.5 to 3 days), with the exceptions of late complications in CNS or kidney (α/β = 2 Gy) or the low α/β ratio for prostate cancer (1.2-1.5 Gy). If this consistent discipline is maintained, then usefully comparable results for BED will be obtained, and their quickly derivable values of normalized total dose (normalized to 2 Gy fractions). The robustness of BED comes basically from the proportionality of BED to alpha, so that reasonable changes in the other parameters have quite small effects on the ratios of BEDs for different schedules. The assumption is not that all the parameters are necessarily absolutely correct (as 'set in stone'), but that they do not differ for similar cohorts of patients. The convenience of NTD (normalized total dose to 2 Gy fractions) is that it is quickly calculable from any BED just by dividing BED (with a repopulation term if necessary) by the relative effectiveness
Gy and the appropriate α/β ratio that was used to obtain the BED (Mehta et al 2001 , Fowler et al 2003a , 2003b , Fowler 2005 . Later work is leading to repopulation corrections which (probably correctly) employ accelerating proliferation rates, and they remain to be validated (Denham and Kron 1996, Fenwick 2006) .
With this new emphasis on the a 1 /a 2 ratio in 1980-82 from Barendsen to correct for fraction size, and on α/β from Thames, Withers & Peters, the Gray Lab made many experimental determinations in mice of these ratios, using all of the late-effect systems listed above and also some implantable mouse tumours (Williams et al 1985) . The results came out entirely consistently with the fewer clinical determinations of α/β, and consistently with our expectations about their relationship with the normal turnover rate of tissues. Bruce Douglas' rapid way of finding α/β was to plot the graph of reciprocal total iso-effective dose against dose-per-fraction, for a constant radiation effect from the different schedules, at the same, preferably short, overall time. A straight line demonstrated that the LQ model was valid. Alpha was the intercept on the reciprocal-total-dose (Y) axis and beta was the slope of the best straight line through the points, which also extrapolated back to minus α/β Gy on the dose-per-fraction (X) axis. Howard Thames showed that this method had the flaw of using dose-per-fraction both in the denominator and the numerator of the ratio, so the apparent 95% confidence limits were not correct even if α/β was. He developed instead a computer method called direct analysis which is now the standard method. Many papers were written, some in collaboration with Howard, during the 1980s. The reciprocal plot method, which Bruce Douglas called the 'Fe method' (for fraction effective, and also out of respect for Frank Ellis, who became 100 years old in 2005 as I write), remains a quick method of estimating an approximate α/β value. (Sadly, Frank Ellis died 5 months later).
Many were the arguments at international meetings between Howard Thames and me about the importance of repopulation, or even its existence. Howard did not want to assign much if any importance to tumour repopulation, and the observations were always that more dose was needed if a treatment took longer. Among the many ingenious alternative arguments, a change in radiosensitivity as treatment proceeded was one. However, if repopulation occurred, the accelerated proliferation led to an increase in the intrinsic radiosensitivity term (alpha), which would require less total dose instead. Another argument was a possible increase in hypoxia, the opposite of re-oxygenation; which is unlikely in a shrinking tumour. Julie Denekamp and I had however seen the effects of repopulation in tumours very clearly and unambiguously through cell kinetics observations in various mouse experiments. I think we won in the end. I remember being thoroughly 'told off' by the distinguished radiation oncologist Maurice Tubiana at a meeting in Italy about 1976: 'Of course, Jack, there is no proliferation in tumours during radiotherapy-everybody knows that the [thymidine] Labelling Index falls to zero in tumours after irradiation, and does not rise again while irradiation continues . . . '. It wasn't until after I had retired from the Gray Lab in 1988 and had time to think in Madison, that I could collect enough clinical data to show that repopulation was very important in human tumours too. 'Oh no, Jack-these are not randomized controlled clinical trials, they are just retrospective data.' Meanwhile, Rod Withers' 'dog-leg' curve (Withers et al 1988) (also of mostly retrospective data from thousands of patients worldwide) was even more convincing than my 12 retrospective series that averaged a 12% loss of local control per week of prolongation in head-and-neck cancer (Fowler and Lindstrom 1992) . Both results still hold today. I support the idea that to neglect retrospective data and carefully observed clinical series, just because they are not randomized into two groups, is to miss out often on important trends.
It was Travis and Tucker (1987) from Howard Thames' institute, who wrote down, apparently without believing it themselves, the appropriate algorithm for two-step repopulation shown in steps 5 to 7 above, that we needed in order to upgrade Barendsen's ERD to the more comprehensive BED. Jan van der Geijn told me about it, and it suddenly went 'Click!' just after I arrived in Madison (Fowler 1989) .
All of this growing experience emphasized the importance of overall time in most types of tumour, with the important exception of prostate cancer. Before I retired from the Gray Lab in 1988 Begg et al (1992 and George Wilson had done much work on the pre-treatment rate of cell birth called T pot (potential doubling time, before allowing for cell loss from apoptosis or nutritional deficiency). They showed that it was faster in most animal and human tumours than in most normal tissues, before any compensatory repopulation stimulated by the treatment. Julie Denekamp and I together with Drs (later Professors) Stanley Dische and Michelle Saunders at the Mount Vernon Regional Radiotherapy Centre designed the CHART schedule (Continuous Hyperfractionated Accelerated Radiation Therapy). This was the shortest that we could design, using three fractions a day with reduced size fractions of 1.5 Gy to avoid late injury, yet to give an approximate 10 logs of cell kill. The overall time was 12 days, or strictly 11.5 days starting at 'day zero' with the first fraction. The minimum interval was 6 h, and was found to fit in with staff if they were allowed flexible hours. This has been much used since then in ten of the regional centres in the UK for lung cancer, because it gives a better tumour result than the standard 60 Gy at 2 Gy fractions. CHART was determined by the UK Ministry of Health to be the most economic treatment for inoperable lung cancer. This schedule was based on the radiobiological theory that the shortest overall time that could be tolerated should be tested, with the smallest doses per fraction that would build up to an adequate dose. However it omitted the consideration of T k , that the shortest overall time need not theoretically be shorter than the kick-off or onset time of tumour cell repopulation, thought now to be 21 to 32 days in head and neck cancer and non-small-cell lung cancer and unlikely to be much shorter; but may be longer in prostate cancer (see section 11). However, for head-and-neck tumours other non-standard fractionation schedules have been found to give better, although not more economical, results than the standard schedules of 3-5 weeks (up to about 11 logs of tumour cell kill, Fowler 2006) . Although economical and effective versus only 60 Gy NTD, the three fractions a day for 12 days without a weekend gap is thought to be organizationally cumbersome for some centres .
It is a relatively new idea in clinical radiotherapy (10 or 15 years) that shorter overall times than 6 or 7 weeks would be worth exploring, first in head and neck tumours and more recently in lung tumours, probably many other types too. As an experimental tumour biologist, I have often wondered why it took so long. As an analyser of clinical results, I look at the confidence intervals and am disappointed to find why! The 95% confidence intervals are so wide, mostly because of too few patients, that most radiobiological parameters are poorly defined. People want more proof than any one trial of even 400 or so patients in two arms can provide.
Radiobiology in the 1990s and 2000s
Radiobiological modelling was then just finding its feet in designing various non-standard fractionation schedules, with head-and-neck schedules leading the way because a 2-or 3-year result was the earliest response among common human tumours for monitoring results. We now had a reasonably reliable way of comparing schedules, and even for estimating a therapeutic gain (tumour BED divided by late normal tissue BED.) The final weapon in the present three-weapon armoury was however proposed only three years ago (Fowler et al 2003b) , making the prediction of an acute BED at last reasonably possible, before actually treating a patient with any proposed new schedule, and together with a dose-escalation introductory trial. The whole procedure then consists of three predictive calculations:
Estimation of late complications BED
with α/β = 3 Gy for most late effects, (except CNS and kidneys where α/β = 2 Gy), and d is the dose per fraction. No allowance for overall time is normally made, because late responding normal tissues have little or no repopulation during the weeks of radiotherapy. For very high total doses, >70 Gy NTD (in 2 Gy fraction equivalent) a volume limitation may be known, like those for area of rectal wall listed by Vargas et al (2005) . For normal tissues with a range of doses across an organ (which is not rare), the equivalent uniform dose EUD is a good way of correcting for the local effect of fraction size (Niemierko) . It can be used with a differential (DVH) dose volume histogram.
From this BED the NTD in 2 Gy fractions is obtained by dividing by 1.67 if α/β = 3 and by 2.0 if α/β = 2 Gy. Most total BEDs should not exceed 117 Gy (NTD 70 Gy), but exceptions occur in brachytherapy for Ca prostate or cervix where BEDs of about 133 Gy3 are given, but with a limitation to only 1 or 2 sq cm of rectal wall (Fowler 2005) .
Estimation of tumour BED
Here T is overall time (the first fraction is given on day 0). T k is the kick-off time for tumour cell repopulation, which occurs at an assumed average doubling time of T p days. T p has been derived from data on delayed treatments in some tumours. For head and neck and for lung tumours, T p = 3 days. T k is less certainly known, but 21-32 days have been suggested so I often assume T k = 28 days. From this BED an NTD is obtained by dividing by 1.2, i.e. by RE for 2 Gy with α/β = 10, (RE = 1 + 2/10). Preferably a corresponding TCP can be looked up from a known dose-response curve derived from a meta-analysis, usually for NTD in 2 Gy fractions. Failing this, a gamma-50 slope of 2.0 or 1.5 could reasonably be assumed for many types of tumour. From the BED, the 'nominal log cell kill' (for a given α/β and α value) can readily be calculated because BED = (log e cell kill)/alpha by definition.
I have found no satisfaction in allowing for hypoxia in tumours-that is, no lack of meaningful correlations by ignoring hypoxia. Furthermore, Overgaard (1994) showed that only 5% of 7921 patients overall (but 7% in head and neck) appeared to be influenced by any of the methods to overcome hypoxia. It appears to me that most tumours might reoxygenate themselves satisfactorily. However, many publications have demonstrated that when a significant proportion of hypoxic cells can be measured in a subset of tumours, for example by electrical probes, the clinical outcome is worse. The topic obviously continues to fascinate the field because the effect is potentially large, where reoxygenation does not solve it naturally. The increasing use of various positron-emitting markers could lead to specific methods for individual patients, and so to choices of chemical radiosensitizers, or treatment for heavy ions rather than photons, and generally individual diagnosis and planning. A very recent publication (Nordsmark et al 2005) has shown that a high degree of hypoxia (defined by the 2.5 mmHg pO 2 level) was significantly linked to treatment failure in an overview of 397 head-and-neck cancer patients from seven centres. The difference in survival at 3 years was 10% (37 versus 47%). Nevertheless, until we routinely identify and treat these patients differently, there seems no point in allowing for hypoxia in quantitative tumour modelling, especially in other body sites. I hope this might change.
Estimation of acute mucosal reaction BED
This is the third weapon in the triple armoury (Fowler et al 2003b) . It is important because if the patients do not tolerate the acute stage of reactions, then that schedule will not be used. Or perhaps it will be used, but with gaps in the treatment which would spoil the tumour effect because of extra tumour cell repopulation, at a rate of about 0.7 Gy 10 , equivalent to 0.6 Gy per day in 2 Gy fraction equivalent dose. The story of the long-term development of this weapon is detailed by Fowler et al (2003) , who found a 'grey zone' of tolerance dose at 59 to 63 Gy 10 (NTD = 49-52.5 Gy in 2 Gy fractions) for head-and-neck patients, if a particular set of parameters was used to calculate the acute BED. These parameters were α/β = 10 Gy; alpha = 0.35 Gy −1 ; T k = 7 days and T p = 2.5 days. This system works for schedules as widely different as the CHART 36F × 1.5 Gy in 11.5 days, to the hyperfractionated 68F × 1.2 Gy or 60F × 1.3 Gy in seven weeks. The field sizes were typically large for head-and-neck treatments before the introduction of IMRT (intensity modified radiotherapy). It is a new game to determine what tolerance doses to specific volumes of tissue might be achievable with IMRT, but the present 59-63 Gy10 and 49-52.5 Gy NTD represent the levels appropriate before IMRT was widely used. It also appears to work for rectal mucosa in patients treated for prostate ontrol carcinoma by hypofractionation at 3 Gy per fraction (Leborgne and Fowler 2005) . This is important in hypofractionation, because if fewer fractions are used, they should sometimes be given on only three or four days per week instead of the usual five, to avoid mucosal over-reactions. For the rectal site, there are also volume constraints at high total doses (Vargas et al 2005) .
Conclusions from modelling head-and-neck non-standard fractionation
It was difficult to find tolerable schedules as short as the theoretically desirable values close to T k , largely because of the limiting acute reactions (Kaanders 2002) . During the 1990s a number of non-standard fractionation schedules were used to treat head-and-neck cancer, with interesting results. Four of these well-known schedules were ingeniously designed to achieve a nominal 11.5 log 10 of cell kill, but they caused too much normal tissue damage-some late but others early-and had to be reduced in total dose or in dose-per-fraction. When adjusted clinically to be acceptable, they were all then found to deliver 11.0-11.2 log 10 cell kill in the present modelling, in agreement with several other well-known schedules that had been found strong but acceptable. All this provides good evidence for the robustness of this modelling. Further, it was found that the acute mucosal tolerance BEDs were reduced from above to below the limiting values set out above as weapon 3 (Fowler et al 2003b) . This means that acute mucosal tolerance is at least as important as late complications, as suggested by Kanders (2002) . This acute mucosal BED is reduced by 0.8 Gy 10 per day (0.67 Gy per day in 2 Gy fractions equivalent) if a few more days are added to the overall time for this adjustment (Fowler 2006) . The late complications were found to be reduced but not to any common level (105-113 Gy 3 instead of 117 Gy 3 ). In 1996 Hendry et al (1996) published a landmark paper in which LQ modelling was used to delineate the loss of local tumour control if one or more treatment days was omitted from a planned radiotherapy treatment. As a result the UK RCR (Royal College of Radiology) proposed rules for correcting for such gaps, and many centres overseas followed them in developing procedures for avoiding gaps. This is an example where radiobiology modelling certainly changed the clinical practice of radiotherapy.
It appears that for tumour cell kill, the level of about 11.0-11.2 log 10 is the maximum that is likely to be possible with radiotherapy alone for head and neck tumours. It remains to be proven whether chemotherapy can add to this without excessive acute reactions. Perhaps IMRT will also enable this tumour log cell kill record to be broken. We are now talking about advanced head-and-neck tumours of stages III and IV. The limiting late complication BED is 117 Gy 3 (NTD = 70 Gy in 2 Gy fractions) and the limiting acute mucosal BED is 59-63 Gy 10 (NTD = 49-52.5 Gy).
This whole question of optimum fractionated radiotherapy for head-and-neck Ca is discussed thoroughly in a chapter being published this year (Fowler 2006 ). The addition of chemotherapy, which for head-and-neck tumours should be done concomitantly, requires that we should choose the best radiotherapy-only schedules. Six such schedules provide just over eleven logs 10 of estimated tumour cell kill, and another six schedules come second with about 10.5 logs (Fowler 2006) . The average 3-year locoregional control values are 54 and 47% respectively for advanced patients, stage III and IV. The briefest summary is that an overall time of 4 or 5 weeks (theoretically, close to T k ) gives the best ratio of log cell kill in tumours to either acute or late complications, and that 2 fractions per day can give about 8% better LRC than once a day. But the bottom line is that we still need reliable tests to choose which patients to offer short radiotherapy schedules to, for specific individuals only. Perhaps it will come from PET scanning (positron emission tomography).
General conclusions about modelling from 1950 to now
Having solved the main problems of non-standard fractionation does not mean that we need no more animal radiobiology. The ability to direct irradiation to millimetre accuracy brings new challenges of just where to place the prescribed margin of a high-dose region. Should it be at least 6-8 mm outside the visualized tumour bulk, as Giraud et al (2000) have suggested based on histologic studies in lung cancer? This question, as it concerns various sites of human tumours, can be answered only by human studies, which are now feasible. But the obverse-where can critical boundaries be placed for normal tissues when quite unusually small volumes can in principle now be selected?-can, and should, be answered by appropriate studies in small animals, with the mini-CT (computer tomography) and mini-MRI (and -MRS) (magnetic resonance imaging and spectroscopy) methods now available, as some small-animal laboratories are now gearing up to do.
One of the most important things about modelling is to answer the criticism of some panicky critics who throw up their hands and say 'Well, you can get any answer you want just by choosing a different set of modelling parameters or variables.' That's not true if you are using the modelling to compare different schedules, say two protocols for treating a given type of tumour, as you usually need to do. There is a natural stability in BED because BED = E/α, and because E and α are proportional to each other, by definition. This means that the ratio of BEDs for two different protocols will vary little for a wide range of reasonable values chosen for the other parameters. The assumption is not that all the radiobiological parameters are absolutely correct (as 'set in stone'), but that the parameters for patients in one set of patients is similar to those in the other set of patients. Unlike some other attempts at modelling, the number of initially viable cells per mm 3 is irrelevant to LQ modelling for time-dose evaluations, being cancelled out against radiosensitivity: (α against BED = E/α) in the standard formulation. This stability is also true of EUD (equivalent uniform dose, the dose that gives the same calculated log cell kill as the DVH you are looking at (Niemierko 1997) ).
A clinically helpful but initially puzzling reversal of radiobiological factors
Before the 1990s we had become accustomed to the dictum that it was best to use a large number of small fractions (1.8-2 Gy) for most situations of malignant tumours close to critical normal tissues, limited only by keeping overall time short so as to avoid some tumour cell repopulation. We were accustomed to assuming α/β = 10 Gy for tumours but α/β = 3 Gy for late complications, the main hazard. Hypofractionation (doses per fraction above about 2 Gy) was considered too damaging for late complications because of the lower α/β ratio However, the realization that it was the slow proliferation in the late responding tissues that was associated with the disproportionate effect of the larger dose-per-fraction-in accordance with LQ modelling-that gave Duchesne and Peters (1999) the idea of suggesting large doses per fraction to treat the slowest growing human tumours, prostate cancer. That realization had been growing for a year or two (Haustermans et al 1997) , and it was Brenner and Hall (1999) who analysed the available clinical data and first showed it to be true in clinical results. A continuous low dose rate from an I-125 permanent implant giving 145 Gy yielded the same local control as half that dose in 2 Gy fractions from linac treatments. Why so different? Radiobiological modelling showed that instead of an α/β ratio of 10 Gy (as in most other tumours), the α/β ratio for prostate tumours was uniquely as low as 1.5 Gy. This inverted the usual ratio with respect to the late complications in rectum, which itself has an α/β ratio of about 3 Gy. Much discussion followed this 'realization from the basic radiobiology' (Fowler et al , 2003a , but later clinical results, not depending on low dose rate treatments, have confirmed that it is true and useful (Fowler 2005 . It is rare that nature hands us a cancer situation where an improved treatment goes hand in hand with a shorter and more convenient one. Radiobiological modelling has aided the acceptance of this unique difference from the earlier general teaching (which is still correct for tumours other than prostate Ca). This exception is for a good radiobiological reason that proliferation in prostate tumours is exceptionally slow. This is another example where radiobiological modelling is changing the clinical practice of cancer treatment, in this case for prostate cancer. Bentzen (2005b) has written a wide-ranging review entitled 'Theragnostic imaging . . . ' which describes the role of visualizing specific cellular biochemical processes, for example by PET scanning of tumours and normal tissue, which might enable treatments to be tailored to the elimination of individual tumours with minimal other radiation damage. Specific targets already in our sights, if not quite in our hands, include rapid repopulation in tumours, or the failure of hypoxic cells to reoxygenate (Nordsmark 2005) , or vulnerability to multi-gene manipulation. These will be exciting steps to explore in the next phase of radiobiology. The continuing virtue of ionizing radiation over any drug or gene-based therapy is that ionizing radiation does certainly reach the cells that the physical plan encompasses, more accurately than ever before.
The future

